The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities

Urmi Dhagat, Timothy R. Hercus, Sophie E. Broughton, Tracy L. Nero, Karen S. Cheung Tung Shing, Emma F. Barry, Christy A. Thomson, Steve Bryson, Emil F. Pai, Barbara McClure, John W. Schrader, Angel F. Lopez, Michael W. Parker

Research output: Contribution to journalArticle

Abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that can stimulate a variety of cells, but its overexpression leads to excessive production and activation of granulocytes and macrophages with many pathogenic effects. This cytokine is a therapeutic target in inflammatory diseases, and several anti-GM-CSF antibodies have advanced to Phase 2 clinical trials in patients with such diseases, e.g., rheumatoid arthritis. GM-CSF is also an essential factor in preventing pulmonary alveolar proteinosis (PAP), a disease associated with GM-CSF malfunction arising most typically through the presence of GM-CSF neutralizing auto-antibodies. Understanding the mechanism of action for neutralizing antibodies that target GM-CSF is important for improving their specificity and affinity as therapeutics and, conversely, in devising strategies to reduce the effects of GM-CSF auto-antibodies in PAP. We have solved the crystal structures of human GM-CSF bound to antigen-binding fragments of two neutralizing antibodies, the human auto-antibody F1 and the mouse monoclonal antibody 4D4. Coordinates and structure factors of the crystal structures of the GM-CSF:F1 Fab and the GM-CSF:4D4 Fab complexes have been deposited in the RCSB Protein Data Bank under the accession numbers 6BFQ and 6BFS, respectively. The structures show that these antibodies bind to mutually exclusive epitopes on GM-CSF; however, both prevent the cytokine from interacting with its alpha receptor subunit and hence prevent receptor activation. Importantly, identification of the F1 epitope together with functional analyses highlighted modifications to GM-CSF that would abolish auto-antibody recognition whilst retaining GM-CSF function. These results provide a framework for developing novel GM-CSF molecules for PAP treatment and for optimizing current anti-GM-CSF antibodies for use in treating inflammatory disorders.

LanguageEnglish
Pages1018-1029
Number of pages12
JournalmAbs
Volume10
Issue number7
DOIs
Publication statusPublished - 3 Oct 2018

Keywords

  • Auto-antibodies
  • Beta common cytokines
  • GM-CSF
  • GM-CSF mutations
  • X-ray crystallography
  • anti-GM-CSF therapeutics
  • pulmonary alveolar proteinosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Dhagat, U., Hercus, T. R., Broughton, S. E., Nero, T. L., Cheung Tung Shing, K. S., Barry, E. F., ... Parker, M. W. (2018). The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. mAbs, 10(7), 1018-1029. https://doi.org/10.1080/19420862.2018.1494107
Dhagat, Urmi ; Hercus, Timothy R. ; Broughton, Sophie E. ; Nero, Tracy L. ; Cheung Tung Shing, Karen S. ; Barry, Emma F. ; Thomson, Christy A. ; Bryson, Steve ; Pai, Emil F. ; McClure, Barbara ; Schrader, John W. ; Lopez, Angel F. ; Parker, Michael W. / The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. In: mAbs. 2018 ; Vol. 10, No. 7. pp. 1018-1029.
@article{a24318dbb18a41b9a1f480c906b23cc2,
title = "The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities",
abstract = "Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that can stimulate a variety of cells, but its overexpression leads to excessive production and activation of granulocytes and macrophages with many pathogenic effects. This cytokine is a therapeutic target in inflammatory diseases, and several anti-GM-CSF antibodies have advanced to Phase 2 clinical trials in patients with such diseases, e.g., rheumatoid arthritis. GM-CSF is also an essential factor in preventing pulmonary alveolar proteinosis (PAP), a disease associated with GM-CSF malfunction arising most typically through the presence of GM-CSF neutralizing auto-antibodies. Understanding the mechanism of action for neutralizing antibodies that target GM-CSF is important for improving their specificity and affinity as therapeutics and, conversely, in devising strategies to reduce the effects of GM-CSF auto-antibodies in PAP. We have solved the crystal structures of human GM-CSF bound to antigen-binding fragments of two neutralizing antibodies, the human auto-antibody F1 and the mouse monoclonal antibody 4D4. Coordinates and structure factors of the crystal structures of the GM-CSF:F1 Fab and the GM-CSF:4D4 Fab complexes have been deposited in the RCSB Protein Data Bank under the accession numbers 6BFQ and 6BFS, respectively. The structures show that these antibodies bind to mutually exclusive epitopes on GM-CSF; however, both prevent the cytokine from interacting with its alpha receptor subunit and hence prevent receptor activation. Importantly, identification of the F1 epitope together with functional analyses highlighted modifications to GM-CSF that would abolish auto-antibody recognition whilst retaining GM-CSF function. These results provide a framework for developing novel GM-CSF molecules for PAP treatment and for optimizing current anti-GM-CSF antibodies for use in treating inflammatory disorders.",
keywords = "Auto-antibodies, Beta common cytokines, GM-CSF, GM-CSF mutations, X-ray crystallography, anti-GM-CSF therapeutics, pulmonary alveolar proteinosis",
author = "Urmi Dhagat and Hercus, {Timothy R.} and Broughton, {Sophie E.} and Nero, {Tracy L.} and {Cheung Tung Shing}, {Karen S.} and Barry, {Emma F.} and Thomson, {Christy A.} and Steve Bryson and Pai, {Emil F.} and Barbara McClure and Schrader, {John W.} and Lopez, {Angel F.} and Parker, {Michael W.}",
year = "2018",
month = "10",
day = "3",
doi = "10.1080/19420862.2018.1494107",
language = "English",
volume = "10",
pages = "1018--1029",
journal = "mAbs",
issn = "1942-0862",
publisher = "Landes Bioscience",
number = "7",

}

Dhagat, U, Hercus, TR, Broughton, SE, Nero, TL, Cheung Tung Shing, KS, Barry, EF, Thomson, CA, Bryson, S, Pai, EF, McClure, B, Schrader, JW, Lopez, AF & Parker, MW 2018, 'The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities', mAbs, vol. 10, no. 7, pp. 1018-1029. https://doi.org/10.1080/19420862.2018.1494107

The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. / Dhagat, Urmi; Hercus, Timothy R.; Broughton, Sophie E.; Nero, Tracy L.; Cheung Tung Shing, Karen S.; Barry, Emma F.; Thomson, Christy A.; Bryson, Steve; Pai, Emil F.; McClure, Barbara; Schrader, John W.; Lopez, Angel F.; Parker, Michael W.

In: mAbs, Vol. 10, No. 7, 03.10.2018, p. 1018-1029.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities

AU - Dhagat, Urmi

AU - Hercus, Timothy R.

AU - Broughton, Sophie E.

AU - Nero, Tracy L.

AU - Cheung Tung Shing, Karen S.

AU - Barry, Emma F.

AU - Thomson, Christy A.

AU - Bryson, Steve

AU - Pai, Emil F.

AU - McClure, Barbara

AU - Schrader, John W.

AU - Lopez, Angel F.

AU - Parker, Michael W.

PY - 2018/10/3

Y1 - 2018/10/3

N2 - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that can stimulate a variety of cells, but its overexpression leads to excessive production and activation of granulocytes and macrophages with many pathogenic effects. This cytokine is a therapeutic target in inflammatory diseases, and several anti-GM-CSF antibodies have advanced to Phase 2 clinical trials in patients with such diseases, e.g., rheumatoid arthritis. GM-CSF is also an essential factor in preventing pulmonary alveolar proteinosis (PAP), a disease associated with GM-CSF malfunction arising most typically through the presence of GM-CSF neutralizing auto-antibodies. Understanding the mechanism of action for neutralizing antibodies that target GM-CSF is important for improving their specificity and affinity as therapeutics and, conversely, in devising strategies to reduce the effects of GM-CSF auto-antibodies in PAP. We have solved the crystal structures of human GM-CSF bound to antigen-binding fragments of two neutralizing antibodies, the human auto-antibody F1 and the mouse monoclonal antibody 4D4. Coordinates and structure factors of the crystal structures of the GM-CSF:F1 Fab and the GM-CSF:4D4 Fab complexes have been deposited in the RCSB Protein Data Bank under the accession numbers 6BFQ and 6BFS, respectively. The structures show that these antibodies bind to mutually exclusive epitopes on GM-CSF; however, both prevent the cytokine from interacting with its alpha receptor subunit and hence prevent receptor activation. Importantly, identification of the F1 epitope together with functional analyses highlighted modifications to GM-CSF that would abolish auto-antibody recognition whilst retaining GM-CSF function. These results provide a framework for developing novel GM-CSF molecules for PAP treatment and for optimizing current anti-GM-CSF antibodies for use in treating inflammatory disorders.

AB - Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic growth factor that can stimulate a variety of cells, but its overexpression leads to excessive production and activation of granulocytes and macrophages with many pathogenic effects. This cytokine is a therapeutic target in inflammatory diseases, and several anti-GM-CSF antibodies have advanced to Phase 2 clinical trials in patients with such diseases, e.g., rheumatoid arthritis. GM-CSF is also an essential factor in preventing pulmonary alveolar proteinosis (PAP), a disease associated with GM-CSF malfunction arising most typically through the presence of GM-CSF neutralizing auto-antibodies. Understanding the mechanism of action for neutralizing antibodies that target GM-CSF is important for improving their specificity and affinity as therapeutics and, conversely, in devising strategies to reduce the effects of GM-CSF auto-antibodies in PAP. We have solved the crystal structures of human GM-CSF bound to antigen-binding fragments of two neutralizing antibodies, the human auto-antibody F1 and the mouse monoclonal antibody 4D4. Coordinates and structure factors of the crystal structures of the GM-CSF:F1 Fab and the GM-CSF:4D4 Fab complexes have been deposited in the RCSB Protein Data Bank under the accession numbers 6BFQ and 6BFS, respectively. The structures show that these antibodies bind to mutually exclusive epitopes on GM-CSF; however, both prevent the cytokine from interacting with its alpha receptor subunit and hence prevent receptor activation. Importantly, identification of the F1 epitope together with functional analyses highlighted modifications to GM-CSF that would abolish auto-antibody recognition whilst retaining GM-CSF function. These results provide a framework for developing novel GM-CSF molecules for PAP treatment and for optimizing current anti-GM-CSF antibodies for use in treating inflammatory disorders.

KW - Auto-antibodies

KW - Beta common cytokines

KW - GM-CSF

KW - GM-CSF mutations

KW - X-ray crystallography

KW - anti-GM-CSF therapeutics

KW - pulmonary alveolar proteinosis

UR - http://www.scopus.com/inward/record.url?scp=85053438452&partnerID=8YFLogxK

U2 - 10.1080/19420862.2018.1494107

DO - 10.1080/19420862.2018.1494107

M3 - Article

VL - 10

SP - 1018

EP - 1029

JO - mAbs

T2 - mAbs

JF - mAbs

SN - 1942-0862

IS - 7

ER -

Dhagat U, Hercus TR, Broughton SE, Nero TL, Cheung Tung Shing KS, Barry EF et al. The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities. mAbs. 2018 Oct 3;10(7):1018-1029. https://doi.org/10.1080/19420862.2018.1494107